EP Patent

EP1326593A1 — ESTROGEN RECEPTOR-$g(b) LIGANDS

Assigned to AstraZeneca AB · Expires 2003-07-16 · 23y expired

What this patent protects

A method for treating a disease associated with the estrogen receptor-β, comprising the step of administiering a therapeutically-effective amount of a compound that satifies the equation: KiαA/KiβA ⊃ 25, optionally having general structure (I).

USPTO Abstract

A method for treating a disease associated with the estrogen receptor-β, comprising the step of administiering a therapeutically-effective amount of a compound that satifies the equation: KiαA/KiβA ⊃ 25, optionally having general structure (I).

Drugs covered by this patent

elacestrant-hydrochloride (ELACESTRANT HYDROCHLORIDE)

Patent Metadata

Patent number: EP1326593A1
Jurisdiction: EP
Classification: —
Expires: 2003-07-16
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.